Physician profile
Peter A Cutri
NPI 1780647990
$4,232.78
in general payments reported to CMS, 2019-2025
31 companies · $449 in 2025
The $449 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $570 · 2021: $741 · 2022: $726 · 2023: $520 · 2024: $555 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $769.89 | 2019-2025 | |
| Genzyme Corporation | $527.70 | 2019-2023 | |
| Biogen, INC. | $259.85 | 2019-2025 | Vumerity, Tysabri |
| Genentech USA, INC. | $237.93 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Abbvie INC. | $230.92 | 2021-2025 | Ubrelvy |
| Lilly USA, LLC | $226.06 | 2020-2025 | Amyvid, Kisunla |
| Janssen Pharmaceuticals, INC | $213.00 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $187.52 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $165.06 | 2020-2025 | |
| Amgen INC. | $155.34 | 2019-2025 | Uplizna |
| Kyowa Kirin, INC. | $143.71 | 2020-2022 | |
| Celgene Corporation | $131.98 | 2021-2025 | Zeposia |
| Pfizer INC. | $107.06 | 2023-2025 | |
| Eisai INC. | $90.70 | 2022-2024 | |
| Sk Life Science, INC. | $82.04 | 2020-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $77.27 | 2020-2021 | |
| Grifols USA, LLC | $73.36 | 2023-2024 | Gamunex-C |
| Acorda Therapeutics, INC | $65.66 | 2019-2020 | |
| Tg Therapeutics, INC. | $65.25 | 2024-2025 | |
| Argenx US, INC. | $61.61 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Nobelpharma America, LLC | $52.43 | 2023 | |
| Allergan, INC. | $50.03 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.76 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $38.54 | 2022 | |
| Greenwich Biosciences, INC. | $34.04 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $31.56 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $27.81 | 2019-2020 | |
| Ucb, INC. | $21.43 | 2021 | |
| Sunovion Pharmaceuticals INC. | $20.50 | 2022 | |
| Neurocrine Biosciences, INC. | $19.60 | 2021 | |
| Avion Pharmaceuticals | $18.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Cutri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.